<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II NoneSmall Cell Lung Cancer: The Mayo Clinic Experience</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Corey</forename><forename type="middle">J</forename><surname>Hobbs</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD, Depart-</roleName><forename type="first">Stephen</forename><forename type="middle">J</forename><surname>Ko</surname></persName>
							<email>ko.stephen@mayo.edu</email>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD;</roleName><forename type="first">Nitesh</forename><forename type="middle">N</forename><surname>Paryani</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joseph</forename><forename type="middle">M</forename><surname>Accurso</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kenneth</forename><forename type="middle">R</forename><surname>Olivier</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Yolanda</forename><forename type="middle">I</forename><surname>Garces</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MS</roleName><forename type="first">Sean</forename><forename type="middle">S</forename><surname>Park</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Christopher</forename><forename type="middle">L</forename><surname>Hallemeier</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Steven</forename><forename type="middle">E</forename><surname>Schild</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Sujay</forename><forename type="middle">A</forename><surname>Vora</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jonathan</forename><forename type="middle">B</forename><surname>Ashman</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">William</forename><forename type="middle">G</forename><surname>Rule</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Johnny</forename><forename type="middle">R</forename><surname>Bowers</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>BS</roleName><forename type="first">Michael</forename><forename type="middle">G</forename><surname>Heckman</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Nancy</forename><forename type="middle">N</forename><surname>Diehl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBA</roleName><forename type="first">Robert</forename><forename type="middle">C</forename><surname>Miller</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ment of Radiation Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>4500 San Pablo Rd</addrLine>
									<postCode>32224</postCode>
									<settlement>Jacksonville</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II NoneSmall Cell Lung Cancer: The Mayo Clinic Experience</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">A4B5AF86E76D23C5AB56F6FE8CFFB2FE</idno>
					<idno type="DOI">10.1016/j.mayocpiqo.2017.11.001</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:48+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective: To examine disease control and survival after stereotactic body radiotherapy (SBRT) for medically inoperable, early-stage nonesmall cell lung cancer (NSCLC) and determine associations of pretreatment 18 F-fluorodeoxyglucoseepositron emission tomography (FDG-PET) maximum standardized uptake values (SUVmax), biologically effective dose, and mediastinal staging with disease control and survival outcomes.</s><s>Patients and Methods: We retrospectively reviewed the cases of consecutive patients with FDG-PETestaged, medically inoperable NSCLC treated with SBRT at our institution between January 1, 2008, and August 4, 2014.</s><s>Cumulative incidences of recurrence were estimated, accounting for the competing risk of death.</s><s>Associations of SUVmax, biologically effective dose, and mediastinal staging with outcomes were evaluated using Cox proportional hazards regression models.</s><s>Results: Among 282 patients, 2-year cumulative incidences of recurrence were 4.9% (95% CI, 2.6%-8.3%)</s><s>for local, 9.8% (95% CI, 6.3%-14.2%)</s><s>for nodal, 10.8% (95% CI, 7.0%-15.5%)</s><s>for ipsilateral lung, 6.0% (3.3%-9.8%)</s><s>for contralateral lung, 9.7% (95% CI, 6.3%-14.0%)</s><s>for distant recurrence, and 26.1% (95% CI, 20.4%-32.0%)</s><s>for any recurrence.</s><s>The 2-year overall survival was 70.4% (95% CI, 64.5%-76.8%),</s><s>and the 2-year disease-free survival was 51.2% (95% CI, 44.9%-58.5%).</s><s>Risk of any recurrence was significantly higher for patients with higher SUVmax (hazard ratio [per each doubling], 1.29 [95% CI, 1.05-1.59];</s><s>P¼.02).</s><s>A similar association with SUVmax was observed when considering the composite outcome of any recurrence or death (hazard ratio, 1.23 [95% CI, 1.05-1.44];</s><s>P¼.01).</s><s>The SUVmax was not significantly associated with other outcomes (P0.69).</s><s>Two-year cumulative incidences of local recurrence for patients receiving 48 Gy in 4 fractions, 54 Gy in 3 fractions, or 50 Gy in 5 fractions were 1.7% (95% CI, 0.3%-5.6%),</s><s>3.7% (95% CI, 0.7%-11.4%),</s><s>and 15.3% (95% CI, 5.9%-28.9%),</s><s>respectively (P¼.02); this difference was independent of lesion size (P¼.02).</s><s>Conclusion: Disease control was excellent for patients who received SBRT for early-stage NSCLC, and this series represents the largest single-institution experience from the United States on SBRT for early-stage inoperable NSCLC.</s><s>Higher pretreatment FDG-PET SUVmax was associated with increased risk of any recurrence, and the 50 Gy in 5 fractions dose prescription was associated with increased risk of local recurrence.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>is the leading cause of cancer death in the United States. <ref type="bibr" target="#b0">1</ref> For patients with early-stage disease, the standard treatment recommendation is surgical resection with mediastinal lymph node dissection or systematic sampling. 2</s><s>However, many patients with NSCLC have cardiac or pulmonary comorbid conditions that prevent them from being appropriate candidates for surgery.</s><s>4]<ref type="bibr">[5]</ref><ref type="bibr">[6]</ref> In more recent series, the LC rates exceed 90%.</s><s>Multiple studies have shown that delivering a higher biologically effective dose (BED) leads to better outcomes. <ref type="bibr">7,</ref><ref type="bibr">8</ref></s><s>he National Comprehensive Cancer Network guidelines provide options for adjuvant therapy after surgical resection on the basis of tumor size, lymphovascular space invasion, tumor grade, and lymph node involvement. <ref type="bibr">2</ref></s><s>Many patients undergoing SBRT, however, have limited tissue to evaluate these pathologic risk factors to guide adjuvant therapy decisions.</s><s>Furthermore, many patients have a clinical diagnosis based solely on radiographic suspicion and patient history, given that biopsy is often considered high risk because of comorbid conditions and poor lung function.</s><s>In these patients, with the limited prognostic information available other than tumor size, metabolic parameters from pretreatment positron emission tomography (PET) have been evaluated as promising prognosticators.</s><s>]<ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref> Unlike surgery, which includes pathologic lymph node assessment, SBRT does not address or treat the potential spread of malignant cells into regional lymph nodes.</s><s>Therefore, regional lymph node evaluation is needed to determine whether patients are appropriate candidates for SBRT. 18</s><s>F-fludeoxyglucoseePET (FDG-PET) has been shown to have excellent diagnostic accuracy, with a negative predictive value of 91%dan improvement compared with computed tomography (CT) alone. <ref type="bibr">18</ref></s><s>any patients also undergo histologic evaluation of lymph nodes with mediastinoscopy or, more commonly, endobronchial ultrasonography (EBUS).</s><s>This further improves the chances of accurately staging disease.</s><s>It is unknown whether histologic evaluation of lymph nodes before SBRT may decrease the risk of subsequent regional failure.</s><s>In one study of patients referred for SBRT after lymph nodeenegative PET-CT results, 16% of patients undergoing EBUS had lymph node involvement. <ref type="bibr" target="#b1">19</ref></s><s>If not evaluated with EBUS, these involved nodes would have posed a risk of subsequent regional failure after treatment with SBRT alone.</s></p><p><s>In this retrospective study, we report outcomes after SBRT for patients with medically inoperable NSCLC at our institution.</s><s>The primary aim was to evaluate disease control and survival outcomes after SBRT, with secondary aims of evaluating potential associations between outcomes and FDG-PET SUVmax, BED, and mediastinal staging.</s><s>Toxicity associated with SBRT will be the subject of a separate future analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATIENTS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Population</head><p><s>Institutional review board approval was obtained for this retrospective review of consecutive patients with NSCLC treated with SBRT at 3 geographically separate campuses of our institution (designated sites 1, 2, and 3) between January 1, 2008, and August 4, 2014.</s><s>Patients were included if they had American Joint Committee on Cancer clinical stage I or II, T1-T3N0M0 NSCLC, as determined by either clinical suspicion or pathologic diagnosis.</s><s>Patients were excluded if they did not undergo FDG-PET staging, if they had a synchronous lung cancer lesion, prior lung cancer, history of other cancer that was possibly presenting as a lung metastasis, or if they did not have any follow-up after SBRT treatment.</s></p><p><s>All patients underwent pretreatment PET.</s><s>Patients were required to have follow-up chest CT, most often performed every 3 months.</s><s>Measured outcomes included local recurrence, nodal recurrence, ipsilateral lung recurrence, contralateral lung recurrence, distant recurrence, any recurrence, disease-free survival (DFS), and overall survival (OS).</s><s>The baseline time point for all outcomes was the day of the first SBRT treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Radiation Treatment</head><p><s>1]<ref type="bibr" target="#b4">[22]</ref><ref type="bibr" target="#b5">[23]</ref> In most cases, a gross tumor volume was created based on lung windows from planning CT.</s><s>Four-dimensional CT was obtained at the time of CT simulation to create an internal target volume (ITV).</s><s>A uniform 5-mm planning target volume expansion was typically performed after ITV creation.</s><s>If no ITV was available, the planning target volume expansion was 5 mm axially and 1 cm in the superior and inferior dimensions.</s><s>Prescription doses ranged from 48 to 60 Gy in 3 to 5 fractions (shown as Gy/fractions).</s><s>Dose constraints for organs at risk were also extrapolated from RTOG protocols.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analyses</head><p><s>The cumulative incidences of local recurrence, nodal recurrence, ipsilateral lung recurrence, contralateral lung recurrence, distant recurrence, and any recurrence were estimated while accounting for the competing risk of death. <ref type="bibr" target="#b6">24</ref></s><s>verall survival and DFS were estimated using the Kaplan-Meier method.</s><s>Censoring occurred at the date of last follow-up.</s></p><p><s>For evaluation of the association between FDG-PET SUVmax and outcomes, unadjusted Cox proportional hazards regression models were used, in which SUVmax was examined on a logarithmic scale owing to its skewed distribution.</s><s>Hazard ratios (HRs) and 95% CIs were estimated, and the cause-specific hazard of the given outcome was modeled. <ref type="bibr" target="#b7">25</ref></s><s>The associations between BED and local recurrence and between mediastinal staging and nodal recurrence were also examined using unadjusted Cox regression models.</s><s>For the association between BED and local recurrence, we also examined the sensitivity of our Cox regression results to the adjustment for lesion size.</s><s>P&lt;.05 was considered statistically significant in all analyses, and all statistical tests were 2-sided.</s><s>Statistical analyses were performed using SAS software, version 9.2 (SAS Institute) and R statistical software, version 3.1.1</s><s>(R Foundation for Statistical Computing).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>Review of patient databases identified a total of 282 patients for inclusion at the 3 sitesd152 at site 1, 69 at site 2, and 61 at site 3. Patient and treatment characteristics are presented in Table <ref type="table" target="#tab_0">1</ref>.</s><s>The median age was 76 years (range, 51-94 years), and 130 patients (46.1%) were men.</s><s>The median tumor size was 2.1 cm, and median FDG-PET SUVmax was 6.5.</s><s>Most patients had either T1a (132 [46.8%]),</s><s>T1b (88 [31.2%]), or T2a (54 [19.1%]) lesions.</s><s>Among the 196 patients (69.5%) who underwent biopsy, most lesions (99 [50.5%]) were diagnosed as adenocarcinoma, 70 (35.7%)</s><s>were squamous cell carcinoma, and 27 (13.8%)</s><s>were not otherwise specified.</s><s>Of the 282 patients, 90 (31.9%) underwent mediastinal lymph node evaluation before treatment, mostly with EBUS.</s><s>The median duration of follow-up after the first SBRT treatment was 20.4 months (range, 2.5-76.6 months).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Clinical Outcomes</head><p><s>A summary of clinical outcomes is provided in Table <ref type="table" target="#tab_3">2</ref>.</s><s>A total of 79 patients (28.0%) had disease recurrence of any type, which corresponds to a 2-year cumulative incidence of 26.1% (95% CI, 20.4%-32.0%).</s><s>The most common type of specific recurrence was ipsilateral lung recurrence, with a 2-year cumulative incidence of 10.8% (95% CI, 7.0%-15.5%),</s><s>followed by nodal recurrence (9.8%; 95% CI, 6.3%-14.2%),</s><s>distant recurrence (9.7%; 95% CI, 6.3%-14.0%),</s><s>contralateral lung recurrence (6.0%; 95% CI, 3.3%-9.8%),</s><s>and local recurrence (4.9%; 95% CI, 2.6%-8.3%</s><s>]<ref type="bibr" target="#b10">[28]</ref><ref type="bibr" target="#b11">[29]</ref><ref type="bibr" target="#b12">[30]</ref><ref type="bibr" target="#b13">[31]</ref><ref type="bibr" target="#b14">[32]</ref><ref type="bibr" target="#b15">[33]</ref><ref type="bibr" target="#b16">[34]</ref><ref type="bibr" target="#b17">[35]</ref><ref type="bibr" target="#b18">[36]</ref><ref type="bibr" target="#b19">[37]</ref> One limitation of our outcome data is that not all patients underwent biopsy before radiation (69.5% biopsy rate).</s><s>However, in other studies reporting outcomes of patients treated with or without biopsy, LC, distant metastasis, and OS appear similar between the groups. <ref type="bibr" target="#b20">38</ref></s><s>In the literature on retrospective studies, the biopsy rate ranges from 35% to 100% (Table <ref type="table" target="#tab_5">4</ref>).</s><s>Examining the prospective data, in which most trials have required a biopsy, the 3-year LC rate ranges from 84% to 98% (Table <ref type="table" target="#tab_5">4</ref>).</s><s>Thus, SBRT appears to result in better LC than conventional external beam radiotherapy, which has LC rates of approximately 70% for stage I NSCLC. <ref type="bibr" target="#b21">39</ref></s><s>In terms of regional control, the 2-year nodal failure rate of 10% in our study is consistent with other retrospective and prospective data showing 4% to 13% nodal failure rates (Table <ref type="table" target="#tab_5">4</ref>).</s><s>Others have shown low rates of nodal failure despite patients having only clinical staging.</s><s>For example, in a retrospective study of 676 patients who underwent SBRT, Senthi et al 6 reported a 2-year regional control rate of 92% for patients with clinical stage I and II NSCLC.</s></p><p><s>Rates of distant metastasis have varied among studies, partly because of the definition of distant metastasis.</s><s>In the current study, we elected to separate contralateral lung nodules from other distant organ failures.</s><s>Our combined rate of contralateral lung failures (6.0%) and other distant failures (9.7%) would be consistent with the failure rates seen in prospective studies. <ref type="bibr">4</ref></s><s>he value of pretreatment FDG-PET in predicting outcomes for inoperable NSCLC treated with SBRT is controversial.</s><s>The available studies report conflicting results.</s><s>Several series showed that PET results are not prognostic for various outcomes such as local failure, regional failure, distant metastasis, DFS, or OS.</s><s>Burdick et al 11 analyzed 72 patients with medically inoperable T1-T2N0M0 NSCLC treated with SBRT and concluded that pretreatment PET SUVmax did not predict LC, regional failure, distant metastasis, or OS.</s><s>Similarly, Hoopes et al <ref type="bibr">10</ref>  predictor of LC or OS.</s><s>Many factors may contribute to the lack of association between PET data and prognosis.</s><s>For example, the particular PET findings that should be evaluateddwhether SUVmax, retention index, metabolic tumor volume, total lesion glycolysis, or some other parameterdhave not been agreed upon.</s><s>Most series have few patients and may not have enough events to show statistical significance for local or regional control.</s><s>Also, other factors may influence the measurement of SUVmax, including duration of fasting time before PET and spatial resolution.</s><s>]<ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref> Clarke et al 14 showed that SUVmax greater than 5 was the most significant cutoff point for predicting distant metastasis (P¼.01).</s><s>Among 152 patients with T1-T2N0M0 NSCLC treated with SBRT, Takeda et al 15 found that an SUVmax greater than 2.47 predicted worse 3-year DFS (58.3% vs 93%; P&lt;.001) and that an SUVmax greater than 2.55 predicted worse 3-year OS (42.2% vs 86.5%; P&lt;.001).</s><s>In the current study, patients with a higher SUVmax were more likely to experience any recurrence compared with patients with a lower SUVmax.</s><s>The overall number of events in our study may be too few to demonstrate an association of SUVmax with any single particular outcome, such as LC, but these events as an aggregate did allow for association to be demonstrated.</s><s>Further prospective studies are needed to determine whether additional treatment in this higher-risk cohort may decrease the risk of recurrence and improve outcomes.</s><s>However, many of these patients have underlying comorbid conditions, and any additional therapy would need to be weighed against possible increases in treatment toxicity in this patient population.</s></p><p><s>Patients treated with higher BED regimens (54/3 or 48/4) had better LC than patients treated with 50/5, and this finding was independent of lesion size.</s><s>Other studies have previously demonstrated that delivering a higher BED can improve outcomes. 7,8</s><s>However, the ideal dose regimen for optimizing LC and minimizing toxicities continues to be a subject of investigation.</s><s>The RTOG 0813 study is a closed phase 1-2 dose escalation trial that will help determine the optimal SBRT dose for medically inoperable, centrally located tumors.</s><s>The starting dose in this trial was 50/5 and was escalated by 2.5 Gy to a maximum dose of 60/5, with maximum tolerated dose and treatment efficacy being the primary end points.</s><s>Early results presented at the American Society for Radiation Oncology 2015 annual meeting regarding toxicity with a median follow-up of 26.6 months showed a maximum tolerated dose of 60/5 with a 7.2% risk of dose-limiting toxicity. <ref type="bibr" target="#b22">40</ref></s><s>The phase 2 efficacy component of the study will help determine the optimal dose for central lesions.</s><s>Given our finding of inferior LC with 50/5, it is possible that one of the higher doses used in RTOG 0813 may be optimal for central lesions.</s></p><p><s>For peripheral lesions, RTOG 0915 is a closed phase 2 trial that compared 48/4 vs 34/1 in patients with medically inoperable NSCLC; the authors concluded that 34/1 should be further researched in future SBRT trials. <ref type="bibr">5</ref></s><s>We found LC to be greater than 95% for patients receiving either 48/4 or 54/3.</s><s>Our study group did not include any patients with single-fraction treatment, so further research will assist in identifying the ideal dose for peripheral lesions.</s><s>This study has limitations inherent to retrospective studies.</s><s>Although treatment was planned based on RTOG protocol guidelines, there was no independent review of treatment plans to ensure that there were no deviations from these guidelines.</s><s>Selection bias may have occurred in patients who underwent EBUS among the 3 treatment sites, which limits our analysis regarding whether EBUS staging can help decrease nodal failures after SBRT.</s><s>Follow-up was typically performed with chest CT every 3 months after completion of treatment, but because this was not a prospective protocol, actual follow-up schedule and studies may have varied between patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p><s>Our analysis of a large cohort of patients with NSCLC confirms the reproducibility of SBRT in multiple smaller trials and helps strengthen the evidence supporting SBRT as an excellent treatment option for medically inoperable early-stage lung cancer.</s><s>We found that higher pretreatment FDG-PET SUVmax was associated with increased risk of any recurrence, and the 50 Gy in 5 fraction prescription was associated with increased risk of local recurrence.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>ª</head><label></label><figDesc><div><p><s>2017 Mayo Foundation for Medical Education and Research.</s><s>Published by Elsevier Inc.</s><s>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc Inn Qual Out 2018;2(1):40-48 N onesmall cell lung cancer (NSCLC)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc><div><p><s>FIGURE 2. Kaplan-Meier curves showing cumulative incidence of local recurrence according to biologically effective dose (n¼271).</s><s>Patients were divided on the basis of Gy fractions: 48 Gy in 4 fractions (n¼148), 50 Gy in 5 fractions (n¼56), or 54 Gy in 3 fractions (n¼67).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Abbreviations and Acronyms: BED = biologically effective dose; CT = computed tomography; DFS = disease-free survival; EBUS = endobronchial ultrasonography; FDG-PET = 18 F-fludeoxyglucoseepositron emission tomography; HR = hazard ratio; ITV = internal target volume; LC = local control; NSCLC = nonesmall cell lung cancer; OS = overall survival; PET = positron emission tomography; RTOG = Radiation Therapy Oncology Group; SBRT = stereotactic body radiotherapy; SUVmax = maximum standardized uptake value Affiliations (Continued from the first page of this article.):</s><s>(M.G.H., N.N.D.), Mayo Clinic, Jacksonville, FL; Department of Radiation Oncology, Mayo Clinic, Rochester, MN (K.R.O., Y.I.G., S.S.P., C.L.H.); and Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, AZ (S.E.S., S.A.V., J.B.A., W.G.R., J.R.B.).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1 .</head><label>1</label><figDesc><div><p><s>Patient and Treatment Characteristics a,b</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell>Value (N¼282)</cell></row><row><cell>Age (y)</cell><cell>76 (51-94)</cell></row><row><cell>Men</cell><cell>130 (46.1)</cell></row><row><cell>Lesion size (cm)</cell><cell>2.1 (0.6-6.6)</cell></row><row><cell>Institution location</cell><cell></cell></row><row><cell>Site 1</cell><cell>152 (53.9)</cell></row><row><cell>Site 2</cell><cell>69 (24.5)</cell></row><row><cell>Site 3</cell><cell>61 (21.6)</cell></row><row><cell>SUVmax T category</cell><cell>6.5 (0.6-38.4)</cell></row><row><cell>1a</cell><cell>132 (46.8)</cell></row><row><cell>1b</cell><cell>88 (31.2)</cell></row><row><cell>2a</cell><cell>54 (19.1)</cell></row><row><cell>3</cell><cell>8 (2.8)</cell></row><row><cell>Biopsy of primary lesion</cell><cell>196 (69.5)</cell></row><row><cell>Histologic diagnosis (N¼196)</cell><cell></cell></row><row><cell>Adenocarcinoma</cell><cell>99 (50.5)</cell></row><row><cell>Squamous cell carcinoma</cell><cell>70 (35.7)</cell></row><row><cell>NOS</cell><cell>27 (13.8)</cell></row><row><cell>Mediastinal staging</cell><cell>90 (31.9)</cell></row><row><cell>BED (Gy/fractions)</cell><cell></cell></row><row><cell>48/4</cell><cell>148 (52.5)</cell></row><row><cell>54/3</cell><cell>67 (23.8)</cell></row><row><cell>50/5</cell><cell>56 (19.9)</cell></row><row><cell>57.5/5</cell><cell>3 (1.1)</cell></row><row><cell>60/5</cell><cell>2 (0.7)</cell></row><row><cell>45/5</cell><cell>1 (0.4)</cell></row><row><cell>50/4</cell><cell>1 (0.4)</cell></row><row><cell>54/5</cell><cell>1 (0.4)</cell></row><row><cell>55/5</cell><cell>1 (0.4)</cell></row><row><cell>56/4</cell><cell>1 (0.4)</cell></row><row><cell>60/3</cell><cell>1 (0.4)</cell></row></table><note><p><s>a BED ¼ biologically effective dose; NOS ¼ not otherwise specified; SUVmax ¼ maximum standardized uptake value.</s><s>b Data are presented as median (range) or No. (percentage) of patients.</s><s>Percentages may not total 100 because of rounding.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 3</head><label>3</label><figDesc></figDesc><table><row><cell cols="2">. Association Between SUVmax and</cell></row><row><cell>Various Outcomes a,b</cell><cell></cell></row><row><cell>Outcome</cell><cell>HR (95% CI) c P value</cell></row><row><cell>Local recurrence</cell><cell>0.91 (0.57-1.45) .69</cell></row><row><cell>Nodal recurrence</cell><cell>0.96 (0.70-1.32) .79</cell></row><row><cell>Ipsilateral lung recurrence</cell><cell>0.97 (0.71-1.33) .84</cell></row><row><cell cols="2">Contralateral lung recurrence 1.04 (0.71-1.52) .85</cell></row><row><cell>Distant recurrence</cell><cell>1.02 (0.73-1.44) .89</cell></row><row><cell>Any recurrence</cell><cell>1.29 (1.05-1.59) .02</cell></row><row><cell>Any recurrence or death</cell><cell>1.23 (1.05-1.44) .01</cell></row><row><cell>Death</cell><cell>1.01 (0.85-1.20) .89</cell></row><row><cell cols="2">a HR ¼ hazard ratio; SUVmax ¼ maximum standardized up-</cell></row><row><cell>take value.</cell><cell></cell></row></table><note><p><s>b HRs, 95% CIs, and P values result from unadjusted Cox proportional hazards models, in which the cause-specific hazard of the given outcome was modeled.</s><s>c HRs for each doubling of SUVmax, which was examined on the logarithmic scale in Cox regression analysis because of skewed distribution.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 2 .</head><label>2</label><figDesc><div><p><s>Summary of Outcomes (N¼282)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell cols="2">Cumulative incidence (95%</cell></row><row><cell></cell><cell></cell><cell cols="2">CI) after SBRT (%)</cell></row><row><cell>Outcome</cell><cell>No. (%) of patients</cell><cell>12 months</cell><cell>24 months</cell></row><row><cell>Local recurrence</cell><cell>15 (5.3)</cell><cell>2.0 (0.7-4.3)</cell><cell>4.9 (2.6-8.3)</cell></row><row><cell>Nodal recurrence</cell><cell>32 (11.3)</cell><cell>5.1 (2.9-8.3)</cell><cell>9.8 (6.3-14.2)</cell></row><row><cell>Ipsilateral lung recurrence</cell><cell>33 (11.7)</cell><cell cols="2">4.0 (2.0-6.9) 10.8 (7.0-15.5)</cell></row><row><cell>Contralateral lung recurrence</cell><cell>23 (8.2)</cell><cell>2.4 (1.0-4.8)</cell><cell>6.0 (3.3-9.8)</cell></row><row><cell>Distant recurrence</cell><cell>29 (10.3)</cell><cell cols="2">7.0 (4.3-10.6) 9.7 (6.3-14.0)</cell></row><row><cell>Any recurrence</cell><cell>79 (28.0)</cell><cell cols="2">14.4 (10.4-19.0) 26.1 (20.4-32.0)</cell></row><row><cell>Any recurrence or death</cell><cell>141 (50.0)</cell><cell cols="2">10.2 (6.6-13.8) 48.8 (41.5-55.1)</cell></row><row><cell>Death</cell><cell>110 (39.0)</cell><cell cols="2">9.7 (6.0-13.2) 29.6 (23.2-35.5)</cell></row><row><cell cols="2">SBRT ¼ stereotactic body radiotherapy.</cell><cell></cell><cell></cell></row></table><note><p><s>DISCUSSIONWe report excellent disease control in this large series of patients who received SBRT for earlystage NSCLC.</s><s>To our knowledge, our study represents the largest single-institution experience from the United States on SBRT for early-stage</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc><div><p><s>reviewed 58 cases of inoperable, clinical stage I NSCLC in prospective phase I and II trials of SBRT and did not find pre-SBRT PET SUVmax to be a</s></p></div></figDesc><table><row><cell>Cumulative incidence of any recurrence (%)</cell><cell>10 20 35 40 50</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0</cell><cell>12</cell><cell>24</cell><cell>36</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Length of time after SBRT (mo)</cell></row><row><cell cols="2">No. at risk</cell><cell></cell><cell></cell><cell></cell></row><row><cell>High</cell><cell></cell><cell>93</cell><cell>46</cell><cell>23</cell><cell>9</cell></row><row><cell cols="2">Moderate</cell><cell>98</cell><cell>66</cell><cell>33</cell><cell>18</cell></row><row><cell>Low</cell><cell></cell><cell>91</cell><cell>58</cell><cell>26</cell><cell>9</cell></row></table><note><p><s>High LowModerate FIGURE 1. Kaplan-Meier curves showing cumulative incidence of recurrence according to maximum standardized uptake values (SUVmax).</s><s>Patients were divided into 3 groups of SUVmax on the basis of sample tertiles: low SUVmax, &lt;4.3 (n¼91), moderate SUVmax, 4.3-8.7 (n¼98), and high SUVmax, &gt;8.7 (n¼93).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>TABLE 4 .</head><label>4</label><figDesc><div><p><s>Comparison of Selected Retrospective and Prospective SBRT Studies , https://www.nccn.org/professionals/physician_gls/pdf/</s><s>nscl.pdf.</s><s>Published October 14, 2016.</s><s>Accessed June 24, 2017.</s><s>3. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al.</s><s>Stereotactic body radiation therapy for early stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.</s><s>Olsen JR, Robinson CG, El Naqa I, et al.</s><s>Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer.</s><s>Int J Radiat Oncol Biol Phys.</s><s>2011;81(4):e299-e303. 9. Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.</s><s>Clin Lung Cancer.</s><s>2008;9(4):217-221.</s><s>10.</s><s>Hoopes DJ, Tann M, Fletcher JW, et al.</s><s>FDG-PET and stereotactic body radiotherapy (SBRT) for stage I nonsmall-cell lung cancer.</s><s>Lung Cancer.</s><s>2007;56(2):229-234.</s><s>11.</s><s>Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.</s><s>Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for earlystage non-small-cell lung cancer treated with stereotactic body radiotherapy.</s><s>Int J Radiat Oncol Biol Phys.</s><s>2010;78(4):1033-1039. 12. Satoh Y, Nambu A, Onishi H, et al.</s><s>Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.</s><s>Eur J Radiol.</s><s>2012;81(11):3530-3534.</s><s>13.</s><s>Takeda A, Yokosuka N, Ohashi T, et al.</s><s>The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).</s><s>Radiother Oncol.</s><s>2011;101(2):291-297. 14.</s><s>Clarke K, Taremi M, Dahele M, et al.</s><s>Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?</s><s>Radiother Oncol.</s><s>2012; 104(1):62-66.</s><s>15.</s><s>Takeda A, Sanuki N, Fujii H, et al.</s><s>Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.</s><s>J Thorac Oncol.</s><s>2014;9(1):65-73.</s><s>16.</s><s>Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR.</s><s>Pretreatment [ 18 F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.</s><s>Int J Radiat Oncol Biol Phys.</s><s>2014;88(2):312-318.</s><s>17.</s><s>Satoh Y, Onishi H, Nambu A, Araki T. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.</s><s>Radiology.</s><s>2014;270(1):275-281. 18. Li X, Zhang H, Xing L, et al.</s><s>Mediastinal lymph nodes staging by 18</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Tumor size (cm)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Reference, year</cell><cell cols="7">No. Med Max Bx proven (%) FU (mo) LC (%) Nodal failure (%) OS (%)</cell></row><row><cell>Retrospective series</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Onimaru et al, 26 2008</cell><cell cols="2">28 NA NA</cell><cell>NA</cell><cell>27</cell><cell>64</cell><cell>NA</cell><cell>NA</cell></row><row><cell>Stephans et al, 27 2009</cell><cell>94 2.3</cell><cell>6</cell><cell>65</cell><cell>15</cell><cell>95</cell><cell>9</cell><cell>75</cell></row><row><cell>Crabtree et al, 28 2010</cell><cell cols="2">76 NA NA</cell><cell>80</cell><cell>19</cell><cell>89</cell><cell>4</cell><cell>32</cell></row><row><cell>Haasbeek et al, 29 2011</cell><cell>63 3.6</cell><cell>7.4</cell><cell>38</cell><cell>35</cell><cell>93</cell><cell>9</cell><cell>69</cell></row><row><cell>Matsuo et al, 30 2012</cell><cell cols="2">66 NA NA</cell><cell>100</cell><cell>36</cell><cell>NA</cell><cell>NA</cell><cell>45</cell></row><row><cell>Senthi et al, 6 2012</cell><cell cols="2">676 2.7 10.7</cell><cell>35</cell><cell>33</cell><cell>95</cell><cell>8</cell><cell>60</cell></row><row><cell>Grills et al, 31 2012</cell><cell>505 2.6</cell><cell>8.5</cell><cell>64</cell><cell>19</cell><cell>94</cell><cell>11</cell><cell>60</cell></row><row><cell>Current series</cell><cell>282 2.1</cell><cell>6.6</cell><cell>70</cell><cell>20</cell><cell>95</cell><cell>10</cell><cell>70</cell></row><row><cell>Prospective series</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Timmerman et al, 32 2006</cell><cell>70 3.1</cell><cell>7</cell><cell>100</cell><cell>18</cell><cell>95</cell><cell>NA</cell><cell>55</cell></row><row><cell>Zimmermann et al, 33 2006</cell><cell cols="2">68 NA NA</cell><cell>100</cell><cell>17</cell><cell>88</cell><cell>6</cell><cell>53</cell></row><row><cell>Fakiris et al, 3 2009</cell><cell>70 NA</cell><cell>7</cell><cell>100</cell><cell>50</cell><cell>88</cell><cell>9</cell><cell>43</cell></row><row><cell>Baumann et al, 34 2009</cell><cell>57 2.5</cell><cell>5</cell><cell>67</cell><cell>35</cell><cell>92</cell><cell>5</cell><cell>65</cell></row><row><cell>Timmerman et al, 4 2010</cell><cell>55 NA</cell><cell>5</cell><cell>100</cell><cell>34</cell><cell>98</cell><cell>4</cell><cell>56</cell></row><row><cell>Ricardi et al, 35 2010</cell><cell>62 2.4</cell><cell>5</cell><cell>65</cell><cell>28</cell><cell>88</cell><cell>13</cell><cell>69</cell></row><row><cell>Bral et al, 36 2011</cell><cell>40 2.8</cell><cell>6</cell><cell>100</cell><cell>16</cell><cell>84</cell><cell>5</cell><cell>52</cell></row><row><cell>Nagata et al, 37 2015</cell><cell>100 2.1</cell><cell>3</cell><cell>100</cell><cell>47</cell><cell>85</cell><cell>8</cell><cell>60</cell></row></table><note><p><s>Bx ¼ biopsy; FU ¼ follow-up; LC ¼ local control; Max ¼ maximum; Med ¼ median; NA ¼ not available; OS ¼ overall survival; SBRT ¼ stereotactic body radiotherapy.</s><s>website</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Mayo Clin Proc Inn Qual Out n March 2018;2(1):40-48 n https://doi.org/10.1016/j.mayocpiqo.2017.11.001 www.mcpiqojournal.org</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2017. National Comprehensive Cancer Network F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study</title>
		<ptr target="http://www.cdc.gov/cancer/lung/statistics/index.htm" />
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="246" to="250" />
			<date type="published" when="2012">May 23, 2017. June 24, 2017.. 2012</date>
		</imprint>
		<respStmt>
			<orgName>Centers for Disease Control and Prevention. Lung cancer statistics. Centers for Disease Control and Prevention website</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sarwate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sarkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Krimsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="81" to="86" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy in treating patients with inoperable stage I or stage II non-small cell lung cancer</title>
		<ptr target="https://clinicaltrials.gov/ct2/show/NCT0087438.ClinicalTrials.govIden-tifier" />
	</analytic>
	<monogr>
		<title level="j">ClinicalTrials.gov website</title>
		<imprint>
			<date type="published" when="2004-07-12">July 12. 2004. February 17, 2017. June 24, 2017</date>
			<publisher>NCT0087438. Published</publisher>
		</imprint>
		<respStmt>
			<orgName>Radiation Therapy Oncology Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy in treating patients with stage I or stage II non-small cell lung cancer that can be removed by surgery</title>
		<ptr target="https://clinicaltrials.gov/ct2/show/NCT00551369.ClinicalTrials.gov" />
	</analytic>
	<monogr>
		<title level="m">Identifier: NCT00551369. Published</title>
				<imprint>
			<date type="published" when="2007-10-31">October 31. 2007. October 27. 2016. June 24, 2017</date>
		</imprint>
		<respStmt>
			<orgName>Radiation Therapy Oncology Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy in treating patients with stage I non-small cell lung cancer</title>
		<ptr target="https://clinicaltrials.gov/ct2/show/NCT00750269" />
	</analytic>
	<monogr>
		<title level="j">ClinicalTrials.gov Identifier: NCT00750269</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2008-05-10">2008. May 10, 2017. June 24, 2017</date>
		</imprint>
		<respStmt>
			<orgName>Radiation Therapy Oncology Group</orgName>
		</respStmt>
	</monogr>
	<note>ClinicalTrials.gov website. Published September</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Radiation therapy in treating patients with stage I non-small cell lung cancer</title>
		<ptr target="https://clinicaltrials.gov/ct2/show/NCT00960999.ClinicalTrials.gov" />
	</analytic>
	<monogr>
		<title level="j">ClinicalTrials. gov website</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<date type="published" when="2009-06-14">2009. June 14, 2017. June 24, 2017</date>
		</imprint>
		<respStmt>
			<orgName>Radiation Therapy Oncology Group</orgName>
		</respStmt>
	</monogr>
	<note>Identifier: NCT00960999. Published August</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Estimation of failure probabilities in the presence of competing risks: new representations of old estimators</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Gooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Leisenring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crowley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Storer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="695" to="706" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Tutorial in biostatistics: competing risks and multi-state models</title>
		<author>
			<persName><forename type="first">H</forename><surname>Putter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fiocco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Geskus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2389" to="2430" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumortracking radiotherapy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Onimaru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamazaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="374" to="381" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Stephans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Djemil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Reddy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="976" to="982" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Crabtree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Denlinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Meyers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="377" to="386" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Outcomes of stereotactic ablative radiotherapy for centrally located earlystage lung cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Haasbeek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lagerwaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Slotman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Senan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2036" to="2043" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shibuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="453" to="456" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Grills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guckenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1382" to="1393" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable earlystage lung cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Timmerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mcgarry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yiannoutsos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="4833" to="4839" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-smallcell lung cancer (NSCLC)</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Geinitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="796" to="801" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hoyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="3290" to="3296" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial</title>
		<author>
			<persName><forename type="first">U</forename><surname>Ricardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Filippi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guarneri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="72" to="77" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gevaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Linthout</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1343" to="1349" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hiraoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shibata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="989" to="996" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Verstegen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lagerwaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Haasbeek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Slotman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Senan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="250" to="254" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The role of radiotherapy in treatment of stage I non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">X</forename><surname>Qiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tullgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lax</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sirzén</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lewensohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bezjak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paulus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Gaspar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="5" to="6" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
